Drugs / MK-2748
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01593735 | May 2012 → Feb 2013 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2748 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01593735 ↗ |
| Modality | Small molecule | — CHEMBL4297303 ↗ |
| Route | Oral | “MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment” NCT01593735 ↗ |